Anbogen Therapeutics, Inc.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
Anbogen’s drug pipeline features two lead small‑molecule candidates: “ABT‑101,” a tyrosine kinase inhibitor targeting HER2 exon20 insertion mutations in non‑small cell lung cancer; and “ABT‑301,” an HDAC1/2/3 inhibitor designed for combination therapy wit
Founded Year
2019
Unified Business No.
82833776
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,145,133,597 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2026)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Anbogen Therapeutics, Inc. is a Taipei‑based clinical‑stage biotech company focused on developing precision oncology drugs, with a mission to transform outcomes for cancer patients through innovative therapies.
